Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness

NCT ID: NCT02125214

Last Updated: 2015-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Temporal dynamics of the EEG microstates show scale-free monofractal properties. This means that information is encoded in the same way at different scales. It may be postulated that these monofractal properties of the EEG microstate sequences constitute a necessary prerequisite of consciousness. We postulate that clinical variations of consciousness may also be linked to alterations of fractal properties of EEG microstates.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Aim of the study: Assess the alteration of temporal organization of EEG microstate sequences during propofol-induced loss of consciousness
* Methods: Prospective clinical trial. 20 right-handed adult patients, aged between 18 and 40 years, scheduled for elective surgery under general anaesthesia, will be included.

Patients will not receive any preoperative oral anxiolysis. After arrival in the operation theatre and a resting period of 10 minutes, the baseline EEG will be recorded (5 minutes duration). Then, after a three minutes proxygenation period with 100% oxygen, patients will receive an intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness. During the induction procedure, the patient's lungs will be gently ventilated using 100% oxygen through a face mask.

Five minutes after reaching each equilibration of the blood-brain propofol concentration, clinical sedation (using the validated six points Observer Assessment of Alertness/Sedation \[OAA/S\] scale) will be annotated. Raw EEG, used later for fractal analysis, will be continuously recorded during the procedure. Corresponding OOA/S scores will be recorded on raw EEG. The study ends 10 minutes after the patient has lost consciousness (absence of response to "mild prodding or shaking" corresponding to OAA/S \<2).

The fractal analysis of EEG will be performed with a delay after anaesthesia by neuroscientists

* Hypothesis: We hypothesise that the fractal properties of EEG microstates will be modified in parallel with the propofol-induced loss of consciousness.
* EEG and DATA analysis Microstate analysis First, we will determine the maxima of the global field power (GFP). Because topography remains stable around peaks of the GFP, they are the best representatives of the momentary map topography in terms of signal-to-noise ratio.18 All maps marked as GFP peaks (i.e., the voltage values at all electrodes at that time point) will be extracted and submitted to a modified spatial cluster analysis using the atomize-agglomerate hierarchical clustering (AAHC) method19 to identify the most dominant map topographies. The optimal number of template maps will be determined by means of a cross-validation criterion.20 We will then submit the template maps identified in every single subject into a second AAHC cluster analysis to identify the dominant clusters across all subjects. Finally, we will compute a spatial correlation between the templates identified at the group level and those identified for each subject in every run. We will so label each individual map with the group template it best corresponds to, to use the same labels for the subsequent group analysis.

Then, we will compute the spatial correlation between the four template maps and the instantaneous EEG21 using a temporal constraint criterion of 32 ms. We will then use these spatial correlation time courses to select the dominant microstate m(k)∈{} at each time instant k and submit those time series to the fractal analysis.

* Fractal analysis We will split the microstate sequence into bipartitions and perform a random walk (on those bipartitions). After having integrated this random walk, we will analyse the integrated random walk by means of the wavelet transform and extract the fractal parameters: Hurst exponent and higher order cumulants.
* Fractal hypothesis One can either expect a decrease of the long-range dependency of the microstate sequences, i.e. one would expect lower Hurst exponents with deeper anaesthesia and hence loss of consciousness. Alternatively, we could also expect a transition from mono- to multifractality, i.e. the scaling of the temporal dynamics of the microstate sequences can be described at the expense of using multiple parameters, i.e. the Hurst exponent and higher-order cumulants that deviate from zero.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Loss of Consciousness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ASA 1-2

ASA 1-2 patients 20-40 yr

Group Type EXPERIMENTAL

Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)

Intervention Type DEVICE

Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)

Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (age between 18 and 40 years)
* Right-handed
* American Society of Anesthesiology (ASA) status I-II
* Scheduled for elective surgery requiring a general anaesthetic
* Able to read and understand the information sheet and to sign and date the consent form.

Exclusion Criteria

* Patients with significant cardio-respiratory or other end-organ disease (renal or hepatic disease influencing metabolism or elimination of study drugs).
* Patients with depression, neurological or psychiatry disorders.
* Dementia or inability to understand the study informed consent.
* Patients with a history of oesophageal reflux, hiatus hernia or any other condition requiring rapid sequence induction of anaesthesia.
* History of drug (opioids) or alcohol abuse.
* Patients with a body mass index \>30 kg m-2.
* Left handed patients
* History of allergy or hypersensitivity to propofol.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Geneva, Switzerland

OTHER

Sponsor Role collaborator

Ecole Polytechnique Fédérale de Lausanne

OTHER

Sponsor Role collaborator

Julien Maillard

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Julien Maillard

Medical Doctor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Tramer, MD, DPhil

Role: STUDY_DIRECTOR

University Hospitals of Geneva, Department of Anesthesiology

Julien Maillard, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals of Geneva, Department of Anesthesiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals of Geneva

Geneva, Canton of Geneva, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Britz J, Van De Ville D, Michel CM. BOLD correlates of EEG topography reveal rapid resting-state network dynamics. Neuroimage. 2010 Oct 1;52(4):1162-70. doi: 10.1016/j.neuroimage.2010.02.052. Epub 2010 Feb 24.

Reference Type BACKGROUND
PMID: 20188188 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Fractal-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

RNS System LGS Feasibility Study
NCT05339126 ACTIVE_NOT_RECRUITING PHASE2